<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00838058</url>
  </required_header>
  <id_info>
    <org_study_id>A6341012</org_study_id>
    <nct_id>NCT00838058</nct_id>
  </id_info>
  <brief_title>A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.</brief_title>
  <official_title>An Open-Label Two-Part Randomized, Crossover Study Of The Pharmacokinetics Of CE-224,535 Administered As Controlled And Immediate Release Formulations In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will try, in 2 separate parts, each using 12 research subjects, to see how a new
      form of the pill CE 224,535 gets released into the bloodstream and whether that is affected
      by food. In each part, subjects will switch among 4 treatment periods to take either
      different forms of the pill(s) or the same form either after fasting or eating a meal. The
      second part will only happen depending on whether the sponsor believes it is needed and will
      use separate subject than the first part.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetic parameters: Tmax, Cmax, AUClast, AUC(0-00), C24, t1/2</measure>
    <time_frame>48 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety parameters including: renal and liver function, blood counts, electrolytes, ECG, and pregnancy testing</measure>
    <time_frame>48 hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part1; controlled release formulation 4; 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one 250 mg controlled release tablet, once in the morning, in fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1; controlled release formulation 4; 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2x250 mg, once in the morning, in fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1; controlled release formula 4; 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4x250 mg tabs, once in the morning, in fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1; controlled release formulation 4; 500 mg FED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2x250 mg, once in the morning , in fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2; IR formulation 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4x125 mg tab of current formulation , once in the morning in the fasted state. This arm will occur as Part 2, only as needed, pending results of Part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2; IR formulation, 500 mg FED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4x125 mg once in the morning in the fed state. This arm will occur as part of Part 2,only as needed, pending results of Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2; controlled release formulation 5;500 mg, FASTED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2x250 controlled release formulation 5 tabs once in the morning in the fasted state. This arm will only occur as part of Part 2, pending results of Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2; controlled release formulation 5;500 mg, FED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2x250 mg controlled release formulation 5 tabs once in the morning in the fed state. This arm will only occur as part of Part 2 pending results of Part 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CE-224,535</intervention_name>
    <description>one 250mg tablet, once in the morning in fasted state</description>
    <arm_group_label>Part1; controlled release formulation 4; 250 mg</arm_group_label>
    <other_name>Part 1;Treatment A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CE-224,535</intervention_name>
    <description>2x250 mg tablets, once in the morning, in fasted state</description>
    <arm_group_label>Part1; controlled release formulation 4; 500 mg</arm_group_label>
    <other_name>Part 1;Treatment B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CE-224,535</intervention_name>
    <description>4x250mg tablets, once in the morning, in fasted state</description>
    <arm_group_label>Part 1; controlled release formula 4; 1000 mg</arm_group_label>
    <other_name>Part 1;Treatment C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CE-224,535</intervention_name>
    <description>2x250mg tab, once in the morning, after being fed a high fat meal</description>
    <arm_group_label>Part 1; controlled release formulation 4; 500 mg FED</arm_group_label>
    <other_name>Part 1;Treatment D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CE-224,535</intervention_name>
    <description>4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.</description>
    <arm_group_label>Part 2; IR formulation 500mg</arm_group_label>
    <other_name>Part 2;Treatment E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CE-224,535</intervention_name>
    <description>4x125 mg IR once in the morning after being fed a high fat meal</description>
    <arm_group_label>Part 2; IR formulation, 500 mg FED</arm_group_label>
    <other_name>Part 2; Treatment F</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CE 224,535</intervention_name>
    <description>2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state</description>
    <arm_group_label>Part 2; controlled release formulation 5;500 mg, FASTED</arm_group_label>
    <other_name>Part 2; Treatment G</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CE 224,535</intervention_name>
    <description>2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal</description>
    <arm_group_label>Part 2; controlled release formulation 5;500 mg, FED</arm_group_label>
    <other_name>Part 2; Treatment H</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 18-55 and healthy

        Exclusion Criteria:

          -  severe chronic or uncontrolled medical or psychiatric conditions, including drug abuse

          -  pregnant or wanting to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6341012&amp;StudyName=A%20study%20in%20normal%20healthy%20people%2C%20testing%20different%20versions%20of%20a%20pill%20that%20will%20be%20used%20to%20treat%20rheumatoid%20arthritis.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2009</study_first_posted>
  <last_update_submitted>October 10, 2009</last_update_submitted>
  <last_update_submitted_qc>October 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>pharmacology formulation normal healthy volunteers food effect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

